Results 51 to 60 of about 786,143 (326)

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.

Clinical Infectious Diseases, 2008
BACKGROUND High functional antibody responses, establishment of immunologic memory, and unambiguous efficacy in infants suggest that an initial dose of conjugated pneumococcal polysaccharide (PnC) vaccine may be of value in a comprehensive adult ...
A. Roux, B. Schmoele-Thoma, G. Siber, J. Hackell, A. Kuhnke, N. Ahlers, S. Baker, A. Razmpour, E. Emini, P. Fernsten, W. Gruber, S. Lockhart, O. Burkhardt, T. Welte, H. Lode   +14 more
semanticscholar   +2 more sources

Risk of transmitting meningococcal infection by transient contact on aircraft and other transport. [PDF]

, 2009
Contact tracing of persons with meningococcal disease who have travelled on aeroplane or other multi-passenger transport is not consistent between countries.
Hellenbrand, W, Krause, G, Rachael, T, Schubert, K, Stuart, JM   +4 more
core   +3 more sources

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

MMWR. Morbidity and mortality weekly report, 2019
Two pneumococcal vaccines are currently licensed for use in adults in the United States: a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Pfizer, Inc.]) and a 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co.
Almea M Matanock, Grace M. Lee, R. Gierke, Miwako Kobayashi, A. Leidner, T. Pilishvili   +5 more
semanticscholar   +1 more source

State of pneumococcal vaccine immunity

Human Vaccines & Immunotherapeutics
Like the other invasive encapsulated bacteria, Streptococcus pneumoniae is also covered with a polysaccharide structure. Infants and elderly are most vulnerable to the invasive and noninvasive diseases caused by S. pneumoniae. Although antibodies against
Mustafa Akkoyunlu
doaj   +1 more source

Meningococcal vaccination in pregnancy

Human Vaccines & Immunotherapeutics, 2018
Invasive meningococcal disease causes meningitis and septicemia worldwide with highest rates of disease occurring in children
Bahaa Abu Raya, Manish Sadarangani
doaj   +1 more source

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

Human Vaccines & Immunotherapeutics, 2018
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global ...
A. W. Dretler, N. G. Rouphael, D. S. Stephens   +2 more
doaj   +1 more source

Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients

Transplantation Direct, 2020
Background. Pneumococcal conjugate vaccination as well as pneumococcal polysaccharide vaccination are recommended for lung transplant candidates and recipients, but the combination of these vaccines has not been extensively studied in these specific ...
Thijs W. Hoffman, MD, Bob Meek, PhD, Ger T. Rijkers, PhD, Jan C. Grutters, MD, PhD, Diana A. van Kessel, MD, PhD   +4 more
doaj   +1 more source

Regulation of surface architecture by symbiotic bacteria mediates host colonization [PDF]

, 2008
Microbes occupy countless ecological niches in nature. Sometimes these environments may be on or within another organism, as is the case in both microbial infections and symbiosis of mammals.
Bry, C. H. Liu, Cerdeno-Tarraga, Comstock, Coyne, D. L. Kasper, Gill, Hooper, J. M. VanLare, Johri, Krinos, Lee, Ley, Mazmanian, Mazmanian, Mazmanian, O'hara, Palmer, Patrick, Patrick, Pizarro-Cerda, S. K. Mazmanian, S. M. Lee, Schembri, Xu, Xu   +25 more
core   +3 more sources

Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.

Journal of Clinical Investigation, 1975
Group A and group C meningoccal polysaccharide vaccines were evaluated in infants. No significant local or systemic reactions were observed with 908 doses of vaccine given to 396 infants between 3 and 12 mo of age.
R. Gold, M. Lepow, I. Goldschneider, T. Draper, E. Gotschlich   +4 more
semanticscholar   +1 more source

Antibody Responses to Meningococcal Polysaccharide Vaccines [PDF]

Infection and Immunity, 1973
Over the past 4 years 19 lots of group C polysaccharide vaccine and five lots of group A polysaccharide vaccine have been tested for their immunogenicity in man. For each lot tested, groups of 18 to 50 men received 50 μg of vaccine subcutaneously. Sera were obtained prior to and 2 weeks after vaccination.
B L Brandt, B L Brandt, Creed D. Smith, Creed D. Smith, Malcolm S. Artenstein, Malcolm S. Artenstein   +5 more
openaire   +3 more sources